Background and Aims: RNA binding motif 10 (RBM10) is a tumour suppressor gene that modulates apoptosis through the regulation of alternative splicing of apoptosis-related genes. Our previous studies suggested that RBM10 overexpression inhibited lung adenocarcinoma cancer cell malignant behaviour in vitro and complementary DNA microarray analysis identified Rap1A was the most downregulated gene by RBM10 overexpression. As one of Ras-associated proteins, Rap1A has been linked to cancer initiation and development. This study aimed to investigate the relationship between RBM10 and Rap1A and the downstream pathways involving in RBM10 induced biological process.
The Second Hospital of Jilin University, China Background and Aims: RNA binding motif 10 (RBM10) is a tumour suppressor gene that modulates apoptosis through the regulation of alternative splicing of apoptosis-related genes. Our previous studies suggested that RBM10 overexpression inhibited lung adenocarcinoma cancer cell malignant behaviour in vitro and complementary DNA microarray analysis identified Rap1A was the most downregulated gene by RBM10 overexpression. As one of Ras-associated proteins, Rap1A has been linked to cancer initiation and development. This study aimed to investigate the relationship between RBM10 and Rap1A and the downstream pathways involving in RBM10 induced biological process.
Methods: Studies were carried out to explore the correlation of RBM10 and Rap1A. Firstly, lentivirus-mediated RBM10 overexpression was employed in lung adenocarcinoma cell line A549 and SPC-A-1.
Then, activated GTP-bound form of Rap1A using pull-down isolation was detected by Rap1A activity assay. Western blotting was carried out to detect RBM10, Rap1A and its downstream factors, phospho-AKT and phospho-CREB which were selected in our previous complementary DNA microarray analysis. Finally, rescue experiment was conducted by upregulating Rap1A expression using 8-pCPT-2'-OMe-cAMP (Epac-selective agonist). Cell viability was assessed using CCK8 assay and expression of downstream factors of Rap1A, phospho-AKT and phospho-CREB were detected by western blot analysis.
Results:
We observed that viability of A549 and SPC-A-1 cells was markedly reduced in RBM10-expressed cells compared to corresponding negative controls and expressions of GTP-bound Rap1A, phospho-AKT and phospho-CREB protein were significantly reduced in RBM10 overexpression group by Rap1A activity assay and western blot analysis. It was found that viability of cells was significantly increased by Rap1A rescue experiment using 8-pCPT-2'-OMe-cAMP and expressions of GTP-bound Rap1A, phospho-AKT and phospho-CREB protein were significantly increased.
Conclusion: This result suggests that RAP1A-AKT-CREB signalling pathway may play an important role in the inhibition of lung cancer induced by RBM10, and it could be an useful predictive signalling pathway, indicating a potentially therapeutic strategy for lung cancer. 
Taiwan
Background and Aims: The first-line epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) had proved significantly longer progression free survival (PFS) in patients who had advanced lung adenocarcinoma harbouring common susceptible EGFR mutation as compared to cytotoxic chemotherapy. However, the efficacy of the firstline EGFR TKI in patients having rare mutation is still unclear.
Methods:
We retrospectively reviewed patients with advanced lung adenocarcinoma who had their specimens tested for EGFR mutation in three Kaohsiung Medical University affiliated hospitals from 2009 to 2017. We recorded their basic characteristics, the response to the EGFR TKI,
PFS and overall survival (OS).
Results: Totally, 2958 patients had their specimens tested for EGFR mutation. In 67 patients having rare mutations and having anti-cancer treatment, 57 patients with stage IV cancer received EGFRTKI, including gefitinib (n = 31), erlotinib (n = 9), and afatinib (n = 17), as the first-line therapy. The mutations in these patients included mutation only in exon 18 (n = 21), exon 20 (n = 16), and exon 21 (n = 13), and mutations in multiple exons (n = 7). The response rates to gefitinib, erlotinib, and afatinib were 41%, 29%, and 33%, respectively (P = 0.7450). There were no significant differences between patients receiving different EGFR TKIs in PFS (The median PFS of patients receiving gefitinib, erlotinib, and afatinib were 6.2, 9.0, and 5.5 months, respectively (P = 0.3025)) and in OS (median OS of patients receiving gefitinib, erlotinib, and afatinib were 16.1, 12.1, and 20.5 months, respectively; P = 0.9116).
Conclusion: First-line gefitinib, erlotinib, and afatinib provided similar clinical efficacy, in terms of response rate, PFS, and OS, in stage IV lung adenocarcinoma patients harbouring rare EGFR mutation. This study may be one of the largest studies comparing the efficacy of different EGFR TKIs to rare mutation. Further large-scale prospective study is warranted. Background and Aims: Cancer diagnosed during pregnancy is rare with a rate of only 0.02-0.1% annually, and lung cancer during pregnancy is even more rare, with only around less than 70 cases reported in the literature. Non-small cell lung cancer (NSCLC) is the most common histological type accounting for 80-85% of all gestational lung cancer This is the case of a 34 year old pregnant female seen at 27 weeks gestational age who presented with a recurrent pleural effusion.
Methods:
The patient underwent repeated thoracenteses. Histopathology and Immunohistochemistry revealed a metastatic adenocarcinoma from a primary pulmonary lesion which was EGFR negative. Chest CT scan showed left parahilar soft tissus fullness, as well as mediastinal and left axillary lymphandenopathies.
Results: A pleural catheter was inserted and a multidisciplinary team was put together to decide the best course of action. The definitive plan was to carry the pregnancy closer to term then to proceed with palliative treatment for the mother with chemotherapy.
Conclusion: Unfortunately, the pregnancy spontaneously terminated before the planned delivery time and the mother proceeded with palliative chemotherapy. 
